PNC Financial Services Group Inc. Sells 3,010 Shares of ANI Pharmaceuticals, Inc. (ANIP)

PNC Financial Services Group Inc. decreased its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 4.1% during the first quarter, Holdings Channel reports. The firm owned 71,268 shares of the specialty pharmaceutical company’s stock after selling 3,010 shares during the period. PNC Financial Services Group Inc.’s holdings in ANI Pharmaceuticals were worth $3,528,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Prudential Financial Inc. raised its position in ANI Pharmaceuticals by 1.4% in the first quarter. Prudential Financial Inc. now owns 14,080 shares of the specialty pharmaceutical company’s stock valued at $697,000 after buying an additional 200 shares during the period. Thrivent Financial for Lutherans raised its position in ANI Pharmaceuticals by 5.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,300 shares of the specialty pharmaceutical company’s stock valued at $261,000 after buying an additional 240 shares during the period. CAPROCK Group Inc. raised its position in ANI Pharmaceuticals by 6.7% in the first quarter. CAPROCK Group Inc. now owns 4,591 shares of the specialty pharmaceutical company’s stock valued at $227,000 after buying an additional 287 shares during the period. Comerica Bank raised its position in ANI Pharmaceuticals by 3.8% in the first quarter. Comerica Bank now owns 8,855 shares of the specialty pharmaceutical company’s stock valued at $486,000 after buying an additional 323 shares during the period. Finally, Teachers Advisors LLC raised its position in ANI Pharmaceuticals by 3.3% in the first quarter. Teachers Advisors LLC now owns 12,604 shares of the specialty pharmaceutical company’s stock valued at $624,000 after buying an additional 398 shares during the period. 55.52% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Shares of ANI Pharmaceuticals, Inc. (ANIP) traded up 0.35% during midday trading on Friday, reaching $45.28. 97,230 shares of the company’s stock traded hands. The company has a market capitalization of $526.92 million, a PE ratio of 141.50 and a beta of 2.95. ANI Pharmaceuticals, Inc. has a 52 week low of $42.56 and a 52 week high of $70.92. The stock’s 50 day moving average is $47.33 and its 200-day moving average is $53.88.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, May 4th. The specialty pharmaceutical company reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.70 by $0.04. The business had revenue of $36.60 million for the quarter, compared to analyst estimates of $39.63 million. ANI Pharmaceuticals had a return on equity of 23.76% and a net margin of 2.58%. The business’s revenue for the quarter was up 77.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.76 earnings per share. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post $3.84 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “PNC Financial Services Group Inc. Sells 3,010 Shares of ANI Pharmaceuticals, Inc. (ANIP)” was first published by WKRB News and is owned by of WKRB News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.wkrb13.com/markets/2230445/pnc-financial-services-group-inc-sells-3010-shares-of-ani-pharmaceuticals-inc-anip.html.

Several research firms have recently weighed in on ANIP. Roth Capital set a $56.00 target price on shares of ANI Pharmaceuticals and gave the company a “hold” rating in a report on Saturday, May 6th. Guggenheim reaffirmed a “buy” rating and set a $80.00 target price on shares of ANI Pharmaceuticals in a report on Thursday, April 6th. ValuEngine lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Finally, TheStreet cut shares of ANI Pharmaceuticals from a “b-” rating to a “c” rating in a research note on Monday, April 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $67.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230445/pnc-financial-services-group-inc-sells-3010-shares-of-ani-pharmaceuticals-inc-anip.html

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.